Skip to Content


In the US, Pegfilgrastim (pegfilgrastim systemic) is a member of the drug class colony stimulating factors and is used to treat Neutropenia Associated with Chemotherapy and Neutropenia Associated with Radiation.

US matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Therapeutic Categories


Colony stimulating factor, granulocyte, G-CSF

Treatment of acute radiation syndrome (ARS)

Chemical Name

Colony-stimulating factor (human), 3-hydroxypropyl-N-metionyl-, 1-eter wit alpha-metyl-omega-hydroxypoly(oxy-1,2-etanediyl)

Foreign Names

  • Pegfilgrastimum (Latin)
  • Pegfilgrastim (German)
  • Pegfilgrastime (French)
  • Pegfilgrastim (Spanish)

Generic Names

  • Pegfilgrastim (OS: BAN, USAN)
  • Pegfilgrastim (Genetical Recombination) (OS: JAN)
  • Filgrastim SD01 (IS)
  • G-CSF (IS)
  • GM-CSF (IS)
  • Pegfilgrastim-jmdb (FDA) (IS)
  • PEG-GCS (IS)
  • PEG-granulocyte-colony stimulating factor (IS)
  • rhG-CSF (IS)
  • rhGM-CSF (IS)
  • SD 01 (IS)
  • SD Neupogen (IS)

Brand Names

  • Fillif-PEG
    Torrent, India
  • Geneleukim
    Geneleuk Biopharmaceutical, China
  • Genfilgras
    Abbott, Colombia
  • G-Lasta
    Kyowa Hakko Kirin, Japan
  • Jiexin
    Zhongkai, China
  • Jimuxin
    NCPC GeneTech, China
  • Neulasta
    Amgen, Australia; Amgen, Belgium; Amgen, Canada; Amgen, Czech Republic; Amgen, Germany; Amgen, Denmark; Amgen, Estonia; Amgen, Spain; Amgen, Finland; Amgen, France; Amgen, United Kingdom; Amgen, Lithuania; Amgen, Latvia; Amgen, Norway; Amgen, Romania; Amgen, Sweden; Amgen, Slovakia; Amgen, United States; Amgen Dompè, Italy; Amgen Europe, Cyprus; Amgen Europe, Croatia (Hrvatska); Amgen Europe, Netherlands; Amgen Europe, Poland; Amgen Europe, Slovenia; Amgen Europe BV, Greece; Amgen Europe BV, Iceland; Amgen Ltd., Ireland; Kyowa Hakko Kirin, South Korea
  • Neulasta 6mg
    Amgen, Hungary; Amgen Europe, Austria; Amgen Switzerland, Switzerland
  • Neulasta-6
    Amgen, Luxembourg
  • Neulastim
    Amgen, Bosnia & Herzegowina; Amgen, Colombia; Amgen, Hong Kong; Amgen, Macedonia; Amgen, New Zealand; Amgen, Oman; Amgen, Serbia; Amgen, Turkey; Amgen Biotecnologia do Brasil, Brazil; Amgen Europe B.V., Israel; Roche, United Arab Emirates; Roche, Armenia; Roche, Netherlands Antilles; Roche, Aruba; Roche, Azerbaijan; Roche, Bahrain; Roche, Belarus; Roche, Ecuador; Roche, Indonesia; Roche, Jamaica; Roche, Kenya; Roche, Kazakhstan; Roche, Sri Lanka; Roche, Morocco; Roche, Moldova; Roche, Mexico; Roche, Nepal; Roche, Philippines; Roche, Pakistan; Roche, Paraguay; Roche, Thailand; Roche, Trinidad & Tobago; Roche, Ukraine; Roche, Uzbekistan; Roche, Yemen; Roche, South Africa; Roche Uruguay, Uruguay; Tecnofarma, Chile; Tecnofarma, Peru
  • Neupopeg
    Dompé, Lithuania
  • Peg Neutropine
    Gemabiotech, Argentina
  • Pegcyte
    Nanogen Pharma, Myanmar
  • Peg-Grafeel
    Dr. Reddy's Laboratories, Vietnam
  • Peglasta
    Kyowa Hakko Kirin, Thailand
  • Ristempa
    Amgen, Australia; Amgen, Estonia; Amgen, Lithuania; Amgen, Sweden


BANBritish Approved Name
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.